Emerging role of proteomics in advancing diagnosis, prognosis, and treatment of liver cancer

Abstract

Liver cancer (LC) remains one of the most prevalent tumors globally. Despite considerable advancements in its clinical treatment in recent years, the global burden of this disease is projected to increase. According to World Health Organization statistics, the number of LC deaths worldwide in 2022 was 760,000, ranking third among all cancers. Therefore, there is an urgent need to delve deeper into the realms of LC diagnosis, prognosis, and treatment. Proteomics, as an emerging technology leveraging mass spectrometry (MS)-based protein identification, liquid chromatography separation, and bioinformatics-driven data integration, enables the systematic characterization of proteome dynamics to address critical challenges in LC research. These challenges include the discovery of diagnostic and prognostic biomarkers as well as therapeutic targets. By scrutinizing the expression of specific proteins in both normal and cancerous tissues through high-throughput protein microarrays, researchers can uncover novel biomarkers. The use of these biomarkers alone or in combination with established ones holds the potential to significantly advance the fields of LC diagnosis, prognosis, and treatment. In general, the application of proteomics has significantly promoted the development of LC research. In this review, we summarized the latest advancements in the application of proteomics in LC, with a particular focus on diagnosis, prognosis, and treatment. We also concluded selected protein markers, aiming to offer guidance for further applications and present additional therapeutic targets for LC.

Keywords

Liver cancer (LC) / Hepatocellular carcinoma (HCC) / Cholangiocarcinoma (CCA) / Proteomics / Diagnosis / Prognosis / Biomarkers / Targeted therapy

References

[1] Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR . A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16:589-604. https://doi.org/10.1038/s41575—019—0186—y.

[2] Huang DQ, Singal AG, Kono Y, Tan DJ, El—Serag HB, Loomba R . Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022; 34:969-977(e2). https://doi.org/10.1016/j.cmet.2022.05.003.

[3] Suresh D, Srinivas AN, Kumar DP . Etiology of hepatocellular carcinoma: special focus on fatty liver disease. Front Oncol . 2020; 10:601710. https://doi.org/10.3389/fonc.2020.601710.

[4] Wang G, Chen Z . HBV genomic integration and hepatocellular carcinoma. Adv Gut Microbiome Res. 2022; 2022:2140886. https://doi.org/10.1155/2022/2140886.

[5] Wu J4, Guo N, Zhang X, et al. HEV—LFs: a novel scoring model for patients with hepatitis E virus—related liver failure. J Viral Hepat. 2019; 26:1334-1343. https://doi.org/10.1111/jvh.13174.

[6] Wu J, Huang F, Ling Z, et al. Altered faecal microbiota on the expression of Th cells responses in the exacerbation of patients with hepatitis E infection. J Viral Hepat. 2020; 27:1243-1252. https://doi.org/10.1111/jvh.13344.

[7] Wong M, Jiang JY, Goggins WB, et al. International incidence and mortality trends of liver cancer: a global profile. Sci Rep . 2017; 7:45846. https://doi.org/10.1038/srep45846.

[8] El—Serag HB . Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142:1264-1273(e1). https://doi.org/10.1053/j.gastro.2011.12.061.

[9] Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition). Liver Cancer. 2018; 7:235-260. https://doi.org/10.1159/000488035.

[10] Xiang Z, Hua M, Hao Z, et al. The roles of mesenchymal stem cells in gastrointestinal cancers. Front Immunol . 2022; 13:844001. https://doi.org/10.3389/fimmu.2022.844001.

[11] Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022; 77:1598-1606. https://doi.org/10.1016/j.jhep.2022.08.021.

[12] Li L, Wang H . Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 2016; 379:191-197. https://doi.org/10.1016/j.canlet.2015.07.018.

[13] Calderaro J, Ziol M, Paradis V, Zucman—Rossi J . Molecular and histological correlations in liver cancer. J Hepatol . 2019; 71:616-630. https://doi.org/10.1016/j.jhep.2019.06.001.

[14] Jiang C, Cai YQ, Yang JJ, et al. Radiomics in the diagnosis and treatment of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2023; 22:346-351. https://doi.org/10.1016/j.hbpd.2023.03.010.

[15] Marko—Varga G, Lindberg H, Löfdahl CG, et al. Discovery of biomarker candidates within disease by protein profiling: principles and concepts. J Proteome Res. 2005; 4:1200-1212. https://doi.org/10.1021/pr050122w.

[16] Aslam B, Basit M, Nisar MA, Khurshid M, Rasool MH . Proteomics: technologies and their applications. J Chromatogr Sci . 2017; 55:182-196. https://doi.org/10.1093/chromsci/bmw167.

[17] Xiang Z, Li J, Lu D, Wei X, Xu X . Advances in multi—omics research on viral hepatitis. Front Microbiol . 2022; 13:3365. https://doi.org/10.3389/fmicb.2022.987324.

[18] Hage DS, Anguizola JA, Bi C, et al. Pharmaceutical and biomedical applications of affinity chromatography: recent trends and developments. J Pharm Biomed Anal. 2012; 69:93-105. https://doi.org/10.1016/j.jpba.2012.01.004.

[19] Sutandy FR, Qian J, Chen CS, Zhu H . Overview of protein microarrays. Curr Protoc Protein Sci. 2013; Chapter 27:Unit 27. https://doi.org/10.1002/0471140864.ps2701s72, 1.

[20] Yates JR III . A century of mass spectrometry: from atoms to proteomes. Nat Methods. 2011; 8:633-637. https://doi.org/10.1038/nmeth.1659.

[21] Bernhardt M, Rech A, Berthold M, et al. SILAC—based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor sensitive and resistant melanoma cells. Front Immunol. 2025; 15:1490821. https://doi.org/10.3389/fimmu.2024.1490821.

[22] Hawkridge AM, Muddiman DC . Mass spectrometry—based biomarker discovery: toward a global proteome index of individuality. Annu Rev Anal Chem (Palo Alto Calif). 2009; 2:265. https://doi.org/10.1146/annurev.anchem.1.031207.112942.

[23] Wulfkuhle JD, Liotta LA, Petricoin EF . Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003; 3:267-275. https://doi.org/10.1038/nrc1043.

[24] Ding Z, Wang N, Ji N, Chen ZS . Proteomics technologies for cancer liquid biopsies. Mol Cancer. 2022; 21:53. https://doi.org/10.1186/s12943—022—01526—8.

[25] Huang H, Yang Y, Zhu Y, et al. Blood protein biomarkers in lung cancer. Cancer Lett. 2022; 551:215886. https://doi.org/10.1016/j.canlet.2022.215886.

[26] Kimhofer T, Fye H, Taylor—Robinson S, Thursz M, Holmes E . Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. Br J Cancer . 2015; 112:1141-1156. https://doi.org/10.1038/bjc.2015.38.

[27] Parikh ND, Mehta AS, Singal AG, Block T, Marrero JA, Lok AS . Biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2020; 29:2495-2503. https://doi.org/10.1158/1055—9965.EPI—20—0005.

[28] Srivastava A, Creek DJ . Discovery and validation of clinical biomarkers of cancer: a review combining metabolomics and proteomics. Proteomics. 2019; 19:1700448. https://doi.org/10.1002/pmic.201700448.

[29] Choudhary C, Mann M . Decoding signalling networks by mass spectrometry—based proteomics. Nat Rev Mol Cell Biol. 2010; 11:427-439. https://doi.org/10.1038/nrm2900.

[30] Mann M . Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol . 2006; 7:952-958. https://doi.org/10.1038/nrm2067.

[31] Lu JC, Zhang PF, Huang XY, et al. Amplification of spatially isolated adenosine pathway by tumor—macrophage interaction induces anti—PD1 resistance in hepatocellular carcinoma. J Hematol Oncol. 2021; 14:1-20. https://doi.org/10.1186/s13045—021—01207—x.

[32] Jin J, Bai L, Wang D, et al. SIRT3—dependent delactylation of cyclin E2 prevents hepatocellular carcinoma growth. EMBO Rep . 2023; 24:e56052. https://doi.org/10.15252/embr.202256052.

[33] Evans C, Noirel J, Ow SY, et al. An insight into iTRAQ: where do we stand now? Anal Bioanal Chem . 2012; 404:1011-1027. https://doi.org/10.1007/s00216—012—5918—6.

[34] Sun S, Lee NP, Poon RT, et al. Oncoproteomics of hepatocellular carcinoma: from cancer markers’ discovery to functional pathways. Liver Int. 2007; 27:1021-1038. https://doi.org/10.1111/j.1478—3231.2007.01533.x.

[35] Omar MA, Omran MM, Farid K, et al. Biomarkers for hepatocellular carcinoma: from origin to clinical diagnosis. Biomedicines. 2023; 11:1852. https://doi.org/10.3390/biomedicines11071852.

[36] Peeters F, Cappuyns S, Piqué—Gili M, et al. Applications of single—cell multi—omics in liver cancer. JHEP Rep. 2024:101094. https://doi.org/10.1016/j.jhepr.2024.101094.

[37] Budnik B, Levy E, Harmange G, Slavov N . SCoPE—MS: mass spectrometry of single Mammalian cells quantifies proteome heterogeneity during cell differentiation. Genome Biol. 2018; 19:1-12. https://doi.org/10.1186/s13059—018—1547—5.

[38] Wu L, Yan J, Bai Y, et al. An invasive zone in human liver cancer identified by Stereo—seq promotes hepatocyte—tumor cell crosstalk, local immunosuppression and tumor progression. Cell Res. 2023; 33:585-603. https://doi.org/10.1038/s41422—023—00831—1.

[39] Yan J, Jiang Z, Zhang S, et al. Spatial‒temporal heterogeneities of liver cancer and the discovery of the invasive zone. Clin Transl Med. 2025; 15:e70224. https://doi.org/10.1002/ctm2.70224.

[40] Zhang Q, Ye M, Lin C, et al. Mass cytometry—based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study. Gut. 2023; 72:996-1006. https://doi.org/10.1136/gutjnl—2022—327496.

[41] Wang YW, Zuo JC, Chen C, Li XH . Post—translational modifications and immune responses in liver cancer. Front Immunol. 2023; 14:1230465. https://doi.org/10.3389/fimmu.2023.1230465.

[42] Qin G, Dang M, Gao H, Wang H, Luo F, Chen R . Deciphering the protein—protein interaction network regulating hepatocellular carcinoma metastasis. Biochim Biophys Acta Proteins Proteom . 2017; 1865:1114-1122. https://doi.org/10.1016/j.bbapap.2017.06.005.

[43] Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T . Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2015; 21:10573. https://doi.org/10.3748/wjg.v21.i37.10573.

[44] Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66:271-289. https://doi.org/10.3322/caac.21349.

[45] He Y, Lu H, Zhang L . Serum AFP levels in patients suffering from 47 different types of cancers and noncancer diseases. Prog Mol Biol Transl Sci . 2019; 162:199-212. https://doi.org/10.1016/bs.pmbts.2019.01.001.

[46] Marrero JA, Feng Z, Wang Y, et al. Alpha—fetoprotein, des—gamma carboxyprothrombin, and lectin—bound alpha—fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009; 137:110-118. https://doi.org/10.1053/j.gastro.2009.04.005.

[47] Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS . Hepatocellualar carcinoma serum markers. Semin Oncol. 2012:410-433. https://doi.org/10.1053/j.seminoncol.2012.05.001.

[48] Yin X, Zhang BH, Qiu SJ, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol . 2012; 19:2869-2876. https://doi.org/10.1245/s10434—012—2328—0.

[49] Fujiyama S, Morishita T, Hashiguchi O, Sato T . Plasma abnormal prothrombin (des—gamma—carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer. 1988; 61:1621-1628. https://doi.org/10.1002/1097—0142(19880415)61:8<1621::aid—cncr2820610820>3.0.co;2—c.

[50] Liang B, Zhong L, He Q, et al. Diagnostic accuracy of serum CA19—9 in patients with cholangiocarcinoma: a systematic review and meta—analysis. Med Sci Monit . 2015; 21:3555-3563. https://doi.org/10.12659/msm.895040.

[51] Kondo N, Murakami Y, Uemura K, et al. Elevated perioperative serum CA 19—9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma. J Surg Oncol. 2014; 110:422-429. https://doi.org/10.1002/jso.23666.

[52] Gu Y, Chen W, Zhao Y, Chen L, Peng T . Quantitative analysis of elevated serum Golgi protein—73 expression in patients with liver diseases. Ann Clin Biochem. 2009; 46:38-43. https://doi.org/10.1258/acb.2008.008088.

[53] Marrero JA, Romano PR, Nikolaeva O, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005; 43:1007-1012. https://doi.org/10.1016/j.jhep.2005.05.028.

[54] Xing H, Qiu H, Ding X, et al. Clinical performance of alpha—L—fucosidase for early detection of hepatocellular carcinoma. Biomark Med. 2019; 13:545-555. https://doi.org/10.2217/bmm—2018—0414.

[55] Cabiati M, Gaggini M, Cesare MM, et al. Osteopontin in hepatocellular carcinoma: a possible biomarker for diagnosis and follow—up. Cytokine . 2017; 99:59-65. https://doi.org/10.1016/j.cyto.2017.07.004.

[56] Da Costa AN, Plymoth A, Santos—Silva D, et al. Osteopontin and latent—TGF β binding—protein 2 as potential diagnostic markers for HBV—related hepatocellular carcinoma. Int J Cancer. 2015; 136:172-181. https://doi.org/10.1002/ijc.28953.

[57] Du Z, Liu X, Wei X, et al. Quantitative proteomics identifies a plasma multiprotein model for detection of hepatocellular carcinoma. Sci Rep . 2020; 10:15552. https://doi.org/10.1038/s41598—020—72510—9.

[58] Wang Z, Gou W, Liu M, Sang W, Chu H, Zhang W . Expression of P53 and HSP70 in chronic hepatitis, liver cirrhosis, and early and advanced hepatocellular carcinoma tissues and their diagnostic value in hepatocellular carcinoma: an immunohistochemical study. Med Sci Monit. 2015; 21:3209-3215. https://doi.org/10.12659/msm.895592.

[59] Tremosini S, Forner A, Boix L, et al. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut. 2012; 61:1481-1487. https://doi.org/10.1136/gutjnl—2011—301862.

[60] Fan Z, Van de Rijn M, Montgomery K, Rouse RV . Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol. 2003; 16:137-144. https://doi.org/10.1097/01.MP.0000052103.13730.20.

[61] Zhou F, Shang W, Yu X, Tian J . Glypican—3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018; 38:741-767. https://doi.org/10.1002/med.21455.

[62] Radwan NA, Ahmed NS . The diagnostic value of arginase—1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar—1. Diagn Pathol. 2012; 7:149. https://doi.org/10.1186/1746—1596—7—149.

[63] Qi Y, Xu F, Chen L, et al. Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma. Oncotarget. 2016; 7:68242-68252. https://doi.org/10.18632/oncotarget.11921.

[64] Naboulsi W, Megger DA, Bracht T, et al. Quantitative tissue proteomics analysis reveals versican as potential biomarker for early—stage hepatocellular carcinoma. J Proteome Res. 2016; 15:38-47. https://doi.org/10.1021/acs.jproteome.5b00420.

[65] Laohaviroj M, Potriquet J, Jia X, et al. A comparative proteomic analysis of bile for biomarkers of cholangiocarcinoma. Tumour Biol. 2017; 39. https://doi.org/10.1177/1010428317705764, 1010428317705764.

[66] Savoy RM, Ghosh PM . The dual role of filamin A in cancer: can’t live with (too much of) it, can’t live without it. Endocr Relat Cancer. 2013; 20:R341-R356. https://doi.org/10.1530/ERC—13—036.

[67] Guo J, Jing R, Zhong JH, et al. Identification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics. Oncotarget. 2017; 8:62011-62028. https://doi.org/10.18632/oncotarget.18782.

[68] Papadas A, Cicala A, Kraus SG, et al. Versican in Tumor Progression, Tumor—Host Interactions, and Cancer Immunotherapy. In: Kovalszky I, Franchi M, Alaniz LD, eds. The Extracellular Matrix and the Tumor Microenvironment. Biology of Extracellular Matrix . 11th ed. Cham: Springer; 2022:93-118. https://doi.org/10.1007/978—3—030—99708—3_5.

[69] Zalewska A, Waszkiewicz N, López—Pintor RM . The use of saliva in the diagnosis of oral and systemic diseases. Dis Markers . 2019. https://doi.org/10.1155/2019/9149503.

[70] Ding F, Sun K, Sun N, Jiang Q, Cao M, Wu Z . iTRAQ—based proteomics reveals SOD2 as a potential salivary biomarker in liver cancer. Int J Biol Markers. 2019; 34:221-231. https://doi.org/10.1177/1724600819841619.

[71] He J, Zheng Z, Liu T, Ao Y, Yang Y, Hu H . Salivary orosomucoid 1 as a biomarker of hepatitis B associated hepatocellular carcinoma. Sci Rep. 2022; 12:15347. https://doi.org/10.1038/s41598—022—18894—2.

[72] Tu J, Wang B, Wang X, et al. Current status and new directions for hepatocellular carcinoma diagnosis. Liver Res . 2024; 8:218-236. https://doi.org/10.1016/j.livres.2024.12.001.

[73] Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology . 2011; 53:1020-1022. https://doi.org/10.1002/hep.24199.

[74] European Association for the Study of the Liver . EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; 69:182-236. https://doi.org/10.1016/j.jhep.2018.03.019.

[75] Abdelhamed W, El—Kassas M . Hepatocellular carcinoma recurrence: predictors and management. Liver Res . 2023; 7:321-332. https://doi.org/10.1016/j.livres.2023.11.004.

[76] Yuan J, Li J, Gao C, Jiang C, Xiang Z, Wu J . Immunotherapies catering to the unmet medical need of cold colorectal cancer. Front Immunol . 2022; 13:1022190. https://doi.org/10.3389/fimmu.2022.1022190.

[77] Xing X, Yuan H, Sun Y, et al. ANXA2Tyr23 and FLNASer2152 phosphorylation associate with poor prognosis in hepatic carcinoma revealed by quantitative phosphoproteomics analysis. J Proteonomics. 2019; 200:111-122. https://doi.org/10.1016/j.jprot.2019.03.017.

[78] Yang YC, Chien MH, Lai TC, et al. Proteomics—based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma. J Biomed Sci. 2021; 28:29. https://doi.org/10.1186/s12929—021—00727—5.

[79] Ying X, Han SX, He CC, et al. Autoantibodies against glucose—regulated protein 78 as serological biomarkers in metastatic and recurrent hepatocellular carcinoma. Oncotarget. 2017; 8:24828-24837. https://doi.org/10.18632/oncotarget.15192.

[80] Xu S, Gao R, Zhou Y, et al. Clinical diagnostic and prognostic potential of NDRG1 and NDRG2 in hepatocellular carcinoma patients. Front Oncol. 2022; 12:862216. https://doi.org/10.3389/fonc.2022.862216.

[81] Cheng J, Xie HY, Xu X, et al. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. Cancer Lett. 2011; 310:35-45. https://doi.org/10.1016/j.canlet.2011.06.001.

[82] Molee P, Adisakwattana P, Reamtong O, et al. Up—regulation of AKAP13 and MAGT1 on cytoplasmic membrane in progressive hepatocellular carcinoma: a novel target for prognosis. Int J Clin Exp Pathol. 2015; 8:9796.

[83] Nicolussi A, D’inzeo S, Capalbo C, Giannini G, Coppa A . The role of peroxiredoxins in cancer. Mol Clin Oncol . 2017; 6:139-153. https://doi.org/10.3892/mco.2017.1129.

[84] Bai B, Lin Y, Hu J, et al. Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients. Oncol Rep. 2019; 41:1539-1548. https://doi.org/10.3892/or.2019.6977.

[85] Warren WG, Osborn M, Yates A, Wright K, O’Sullivan SE . The emerging role of fatty acid binding protein 5 (FABP5) in cancers. Drug Discov Today . 2023; 28:103628. https://doi.org/10.1016/j.drudis.2023.103628.

[86] Seo J, Jeong DW, Park JW, Lee KW, Fukuda J, Chun YS . Fatty—acid—induced FABP5/HIF—1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells. Commun Biol. 2020; 3:638. https://doi.org/10.1038/s42003—020—01367—5.

[87] Wesener MC, Weiler SM, Bissinger M, et al. CRKL enhances YAP signaling through binding and JNK/JUN pathway activation in liver cancer. Int J Mol Sci. 2024; 25:8549. https://doi.org/10.3390/ijms25158549.

[88] Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV—related hepatocellular carcinoma. Cell. 2019; 179:561-577 (e22). https://doi.org/10.1016/j.cell.2019.08.052.

[89] Wang H, Yang L, Liu M, Luo J . Protein post—translational modifications in the regulation of cancer hallmarks. Cancer Gene Ther. 2022:1-19. https://doi.org/10.1038/s41417—022—00464—3.

[90] Christensen MV, Høgdall CK, Jochumsen KM, Høgdall EV . Annexin A2 and cancer: a systematic review. Int J Oncol. 2018; 52:5-18. https://doi.org/10.3892/ijo.2017.4197.

[91] Wu YY, Yang YP, Li ZQ . Glucose regulated protein 78 kD. Sheng Li Ke Xue Jin Zhan [Progress in Physiology] . 2009; 40:135-141.

[92] Birge RB, Kalodimos C, Inagaki F, Tanaka S . Crk and CrkL adaptor proteins: networks for physiological and pathological signaling. Cell Commun Signal. 2009; 7:13. https://doi.org/10.1186/1478—811X—7—13.

[93] Leutert M, Entwisle SW, Villén J . Decoding post—translational modification crosstalk with proteomics. Mol Cell Proteomics. 2021; 20:100129. https://doi.org/10.1016/j.mcpro.2021.100129.

[94] Wang J, Lou Y, Peng X, et al. Comprehensive analysis of protein post—translational modifications reveals PTPN2—STAT1—AOX axis—mediated tumor progression in hepatocellular carcinomas. Transl Oncol. 2025; 53:102275. https://doi.org/10.1016/j.tranon.2025.102275.

[95] Gao H, Li K, Tu H, et al. Development of T cells redirected to glypican—3 for the treatment of hepatocellular carcinoma. Clin Cancer Res. 2014; 20:6418-6428. https://doi.org/10.1158/1078—0432.CCR—14—1170.

[96] Wang Y, Zhao Y, Li M, et al. Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP—targeted CAR T—cell therapy: a case report. Front Immunol. 2023; 14:1180001. https://doi.org/10.3389/fimmu.2023.1180001.

[97] Chu H, Wu C, Zhao Q, et al. Quantitative proteomics identifies FOLR1 to drive sorafenib resistance via activating autophagy in hepatocellular carcinoma cells. Carcinogenesis. 2021; 42:753-761. https://doi.org/10.1093/carcin/bgab019.

[98] Zhang Q, Zhang Y, Sun S, et al. ACOX2 is a prognostic marker and impedes the progression of hepatocellular carcinoma via PPARα pathway. Cell Death Dis . 2021; 12:15. https://doi.org/10.1038/s41419—020—03291—2.

[99] Liang X, Yao J, Cui D, et al. The TRAF2—p62 axis promotes proliferation and survival of liver cancer by activating mTORC1 pathway. Cell Death Differ . 2023; 30:1550-1562. https://doi.org/10.1038/s41418—023—01164—7.

[100] Arechederra M, Bazai SK, Abdouni A, et al. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol. 2021; 74:893-906. https://doi.org/10.1016/j.jhep.2020.11.008.

[101] Cheng S, Jiang X, Ding C, et al. Expression and critical role of interleukin enhancer binding factor 2 in hepatocellular carcinoma. Int J Mol Sci . 2016; 17:1373. https://doi.org/10.3390/ijms17081373.

[102] Shen XT, Xie SZ, Zheng X, et al. Cirrhotic—extracellular matrix attenuates aPD—1 treatment response by initiating immunosuppressive neutrophil extracellular traps formation in hepatocellular carcinoma. Exp Hematol Oncol. 2024; 13:20. https://doi.org/10.1186/s40164—024—00476—9.

[103] Dong R, Fei Y, He Y, et al. Lactylation—driven HECTD2 limits the response of hepatocellular carcinoma to lenvatinib. Adv Sci (Weinh) . 2025:2412559. https://doi.org/10.1002/advs.202412559.

[104] Strating JR, Martens GJ . The p24 family and selective transport processes at the ER—Golgi interface. Biol Cell. 2009; 101:495-509. https://doi.org/10.1042/BC20080233.

[105] Aber R, Chan W, Mugisha S, Jerome—Majewska LA . Transmembrane emp24 domain proteins in development and disease. Genet Res (Camb) . 2019; 101:e14. https://doi.org/10.1017/S0016672319000090.

[106] De Vitis M, Berardinelli F, Sgura A . Telomere length maintenance in cancer: at the crossroad between telomerase and alternative lengthening of telomeres (ALT). Int J Mol Sci . 2018; 19:606. https://doi.org/10.3390/ijms19020606.

[107] Daniel M, Peek GW, Tollefsbol TO . Regulation of the human catalytic subunit of telomerase (hTERT). Gene . 2012; 498:135-146. https://doi.org/10.1016/j.gene.2012.01.095.

[108] Liu T, Li W, Lu W, et al. RBFOX3 promotes tumor growth and progression via hTERT signaling and predicts a poor prognosis in hepatocellular carcinoma. Theranostics. 2017; 7:3138-3154. https://doi.org/10.7150/thno.19506.

[109] Shi YH, Ding WX, Zhou J, et al. Expression of x—linked inhibitor—of—apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology. 2008; 48:497-507. https://doi.org/10.1002/hep.22393.

[110] Che Y, Ye F, Xu R, et al. Co—expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma. Am J Pathol. 2012; 180:1798-1807. https://doi.org/10.1016/j.ajpath.2012.01.016.

[111] Tey SK, Wong SWK, Chan JYT, et al. Patient pIgR—enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma. J Hepatol. 2022; 76:883-895. https://doi.org/10.1016/j.jhep.2021.12.005.

[112] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359:378-390. https://doi.org/10.1056/NEJMoa0708857.

[113] Zhu YJ, Zheng B, Wang HY, Chen L . New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017; 38:614-622. https://doi.org/10.1038/aps.2017.5.

[114] Chandler KB, Brnakova Z, Sanda M, et al. Site—specific glycan microheterogeneity of inter—alpha—trypsin inhibitor heavy chain H4. J Proteome Res . 2014; 13:3314-3329. https://doi.org/10.1021/pr500394z.

[115] Lee EJ, Yang SH, Kim KJ, et al. Inter—alpha inhibitor H4 as a potential biomarker predicting the treatment outcomes in patients with hepatocellular carcinoma. Cancer Res Treat. 2018; 50:646-657. https://doi.org/10.4143/crt.2016.550.

[116] Monte MJ, Alonso—Peña M, Briz O, et al. ACOX2 deficiency: an inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia. J Hepatol (Amst) . 2017; 66:581-588. https://doi.org/10.1016/j.jhep.2016.11.005.

[117] Borghi A, Verstrepen L, Beyaert R . TRAF2 multitasking in TNF receptor—induced signaling to NF—κB, MAP kinases and cell death. Biochem Pharmacol. 2016; 116:1-10. https://doi.org/10.1016/j.bcp.2016.03.009.

[118] Bader HL, Wang LW, Ho JC, et al. A disintegrin—like and metalloprotease domain containing thrombospondin type 1 motif—like 5 (ADAMTSL5) is a novel fibrillin—1—, fibrillin—2—, and heparin—binding member of the ADAMTS superfamily containing a netrin—like module. Matrix Biol. 2012; 31:398-411. https://doi.org/10.1016/j.matbio.2012.09.008.

[119] Wang J, Ma L, Weng W, et al. Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer. Hepatology. 2013; 58:1011-1020. https://doi.org/10.1002/hep.26420.

[120] Du H, Le Y, Sun F, Li K, Xu Y . ILF2 directly binds and stabilizes CREB to stimulate malignant phenotypes of liver cancer cells. Anal Cell Pathol (Amst) . 2019:1575031. https://doi.org/10.1155/2019/1575031.

[121] Jiang Y, Sun A, Zhao Y, et al. Proteomics identifies new therapeutic targets of early—stage hepatocellular carcinoma. Nature. 2019; 567:257-261. https://doi.org/10.1038/s41586—019—0987—8.

[122] Li B, Li Y, Zhou H, et al. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma. Hepatology. 2024; 79:289-306. https://doi.org/10.1097/HEP.0000000000000553.

[123] Yokoo H, Kondo T, Fujii K, Yamada T, Todo S, Hirohashi S . Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology. 2004; 40:609-617. https://doi.org/10.1002/hep.20372.

[124] Rosic G, Selakovic D, Omarova S . Cancer signaling, cell/gene therapy, diagnosis and role of nanobiomaterials. Advances in Biology & Earth Sciences . 2024; 9:11-34. https://doi.org/10.62476/abes9s11.

[125] Huseynov E, Khalilov R, Mohamed AJ . Novel nanomaterials for hepatobiliary diseases treatment and future perspectives. Advances in Biology & Earth Sciences . 2024; 9:81-91. https://doi.org/10.62476/abes9s81.

[126] Hajiyeva A, Mamedov C, Gasimov E, et al. Ultrastructural investigation of iron oxide nanoparticles accumulation in the liver of common carp (Cyprinus carpio Linnaeus, 1758). Aquat Toxic. 2024; 272:106961. https://doi.org/10.1016/j.aquatox.2024.106961.

[127] Tao Z, Zhu H, Zhang J, et al. Recent advances of eosinophils and its correlated diseases. Front Public Health . 2022; 10:954721. https://doi.org/10.3389/fpubh.2022.954721.

[128] Shen Y, Chen JX, Li M, et al. Role of tumor—associated macrophages in common digestive system malignant tumors. World J Gastrointest Oncol. 2023; 15:596-616. https://doi.org/10.4251/wjgo.v15.i4.596.